Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| NGM Biopharmaceuticals Australia Pty Ltd | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Type 2 Diabetes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NGM282 Dose 1 | Experimental | NGM Dose 1 |
|
| NGM282 Dose 2 | Experimental | NGM Dose 2 |
|
| NGM282 Dose 3 | Experimental | NGM Dose 3 |
|
| Placebo | Placebo Comparator | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NGM282 | Biological |
| ||
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Fasting Plasma Glucose | 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| HbA1c | 28 days | |
| Lipids | 28 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alex M DePaoli, MD | NGM Biopharmaceuticals, Inc | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| NGM Clinical Study Site 6103 | Melbourne | Victoria | Australia | |||
| NGM Clinical Study Site 6104 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30862680 | Derived | DePaoli AM, Zhou M, Kaplan DD, Hunt SC, Adams TD, Learned RM, Tian H, Ling L. FGF19 Analog as a Surgical Factor Mimetic That Contributes to Metabolic Effects Beyond Glucose Homeostasis. Diabetes. 2019 Jun;68(6):1315-1328. doi: 10.2337/db18-1305. Epub 2019 Mar 12. |
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000710649 | aldafermin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Other |
|
| Melbourne |
| Victoria |
| Australia |
| NGM Clinical Study Site 6101 | Perth | Western Australia | Australia |
| NGM Clinical Study Site 6403 | Auckland | New Zealand |
| NGM Clinical Study Site 6405 | Auckland | New Zealand |
| NGM Clinical Study Site 6401 | Christchurch | New Zealand |
| NGM Clinical Study Site 6406 | Dunedin | New Zealand |
| NGM Clinical Study Site 6404 | Tauranga | New Zealand |
| NGM Clinical Study Site 6402 | Wellington | New Zealand |